Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Michigan | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This prospective clinical randomized controlled trial is established to compare the clinical, radiographic, and histological treatment outcomes between MTA and FC in pulpotomized human primary molars at 6, 12, 18, 24 month post-treatment and to test the hypothesis that Gray Mineral Trioxide Aggregate (GMTA) is a viable alternative to Diluted (20%) Formocresol (DFC) in pulpotomies treatment of human primary molars.
Background: Formocresol (FC) is the most widely used pulpotomy medicament in the primary dentition. There are concerns associated with this medicament, primarily the carcinogenicity of the chemical and internal resorption of the treated tooth. Recently, Mineral Trioxide Aggregate (MTA) has been suggested with preliminary studies showing promising results.
Study design: This is a prospective clinical randomized controlled trial (RCT), which will be performed at Department of Dentistry, National Taiwan University Hospital, to compare the treatment outcomes between MTA and FC in pulpotomized human primary molars and to evaluate whether GMTA is a viable alternative to DFC in pulpotomies treatment of human primary molars.
Hypotheses:
Specific Aims:
The primary aims of this investigation are:
The secondary aims of this investigation are:
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| GMTA | Experimental |
| |
| 20% FC | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Gray Mineral Trioxide Aggregate (GMTA) | Drug | Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material. |
| Measure | Description | Time Frame |
|---|---|---|
| clinically and radiographically outcomes | 6, 12, 18, and 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| histological outcome | when the subjective tooth physically exfoliates from oral cavity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Yuan-Ling Lee, PhD | Contact | 886-2-23123456 | 67337 | yuanlinglee@ntu.edu.tw |
| Hsiao-Hua Chang, MS | Contact | 886-2-23123456 | 70251 | hhchangpedo@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Yuan-Ling Lee, PhD | Department of Dentistry, National Taiwan University Hospital | Principal Investigator |
| Hsiao-Hua Chang, MS | Department of Dentistry, National Taiwan University Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Dentistry, National Taiwan University Hospital | Recruiting | Taipei | 10048 | Taiwan |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Jun 27, 2016 | |
| Reset | Aug 3, 2016 | |
| Release | Aug 4, 2016 | |
| Reset | Sep 28, 2016 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Jun 27, 2016 | Aug 3, 2016 | |||
| Aug 4, 2016 |
| ID | Term |
|---|---|
| D003731 | Dental Caries |
| D011671 | Pulpitis |
| ID | Term |
|---|---|
| D017001 | Tooth Demineralization |
| D014076 | Tooth Diseases |
| D009057 | Stomatognathic Diseases |
| D003788 | Dental Pulp Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000624565 | ProRoot MTA |
| C031025 | formocresol |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Diluted (20%) Formocresol (DFC) | Drug | After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material. |
|
|
| Sep 28, 2016 |